Compare Stocks: CAPR, ZBIO, NUVB, and ALVO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$4.58 -4.4%	$5.27	$2.94 ▼ $8.50	$1.38B	0.2	1.09 million shs	666,200 shs
CAPR Capricor Therapeutics	$5.93 -3.3%	$8.21	$2.96 ▼ $40.37	$344.76M	0.61	3.64 million shs	1.46 million shs
NUVB Nuvation Bio	$4.57 -2.9%	$5.86	$3.92 ▼ $9.75	$1.60B	1.61	5.69 million shs	3.19 million shs
ZBIO Zenas BioPharma	$26.87 -4.8%	$29.83	$13.50 ▼ $44.60	$1.75B	-0.9	631,257 shs	377,545 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	0.00%	-8.40%	-22.11%	+49.67%	-44.35%
CAPR Capricor Therapeutics	0.00%	-11.62%	-30.81%	-69.90%	-4.82%
NUVB Nuvation Bio	0.00%	+2.95%	-20.10%	-29.15%	+10.69%
ZBIO Zenas BioPharma	0.00%	+8.17%	-2.29%	-11.58%	+10.26%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$4.58 -4.4%	$5.27	$2.94 ▼ $8.50	$1.38B	0.2	1.09 million shs	666,200 shs
CAPR Capricor Therapeutics	$5.93 -3.3%	$8.21	$2.96 ▼ $40.37	$344.76M	0.61	3.64 million shs	1.46 million shs
NUVB Nuvation Bio	$4.57 -2.9%	$5.86	$3.92 ▼ $9.75	$1.60B	1.61	5.69 million shs	3.19 million shs
ZBIO Zenas BioPharma	$26.87 -4.8%	$29.83	$13.50 ▼ $44.60	$1.75B	-0.9	631,257 shs	377,545 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	0.00%	-8.40%	-22.11%	+49.67%	-44.35%
CAPR Capricor Therapeutics	0.00%	-11.62%	-30.81%	-69.90%	-4.82%
NUVB Nuvation Bio	0.00%	+2.95%	-20.10%	-29.15%	+10.69%
ZBIO Zenas BioPharma	0.00%	+8.17%	-2.29%	-11.58%	+10.26%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	2.29	Hold	$8.50	85.59% Upside
CAPR Capricor Therapeutics	2.27	Hold	$30.25	410.12% Upside
NUVB Nuvation Bio	2.67	Moderate Buy	$13.22	189.58% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$46.71	73.85% Upside

Current Analyst Ratings Breakdown

Latest CAPR, ZBIO, NUVB, and ALVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/23/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/23/2026	ZBIO Zenas BioPharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/20/2026	ALVO Alvotech	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/20/2026	ZBIO Zenas BioPharma	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Equal Weight	$32.00
10/19/2026	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Outperform
10/15/2026	NUVB Nuvation Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	ZBIO Zenas BioPharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$44.00
10/8/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/6/2026	ALVO Alvotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/6/2026	ZBIO Zenas BioPharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/30/2026	ZBIO Zenas BioPharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$41.00 ➝ $48.00

(Data available from 10/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.95M	2.81	$0.22 per share	21.02	($0.94) per share	-4.87
CAPR Capricor Therapeutics	$22.27M	15.48	N/A	N/A	$5.53 per share	1.07
NUVB Nuvation Bio	$62.90M	25.49	N/A	N/A	$0.88 per share	5.19
ZBIO Zenas BioPharma	$10M	175.14	N/A	N/A	$4.51 per share	5.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	$27.92M	-$0.61	N/A	20.82	N/A	-36.31%	N/A	-11.73%	11/11/2026 (Estimated)
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.44	N/A	N/A	N/A	-88.18%	-46.59%	-22.01%	11/4/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.99	N/A	N/A	N/A	N/A	-122.45%	-58.04%	11/18/2026 (Estimated)

Latest CAPR, ZBIO, NUVB, and ALVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/18/2026	Q3 2026	ZBIO Zenas BioPharma	-$1.24	N/A	N/A	N/A	$1.01 million	N/A
11/11/2026	Q3 2026	ALVO Alvotech	-$0.0197	N/A	N/A	N/A	$134.22 million	N/A
11/9/2026	Q3 2026	CAPR Capricor Therapeutics	-$0.1278	N/A	N/A	N/A	$41.71 million	N/A
11/4/2026	Q3 2026	NUVB Nuvation Bio	-$0.1236	N/A	N/A	N/A	$34.39 million	N/A
8/20/2026	Q2 2026	ALVO Alvotech	-$0.0526	-$0.11	-$0.0574	-$0.2230	$103.00 million	$106.00 million
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/13/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	-$1.77	-$0.65	-$1.77	$15.00 million	$1.00 million
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	-$0.15	-$0.0083	-$0.18	$27.03 million	$31.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.65	0.96
CAPR Capricor Therapeutics	N/A	7.35	7.35
NUVB Nuvation Bio	0.96	8.37	8.14
ZBIO Zenas BioPharma	1.57	9.93	9.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
CAPR Capricor Therapeutics	21.68%
NUVB Nuvation Bio	61.67%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	0.46%
CAPR Capricor Therapeutics	9.20%
NUVB Nuvation Bio	30.11%
ZBIO Zenas BioPharma	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,460	301.81 million	300.42 million	Not Optionable
CAPR Capricor Therapeutics	231	58.14 million	52.79 million	Optionable
NUVB Nuvation Bio	305	351.12 million	245.40 million	Optionable
ZBIO Zenas BioPharma	167	65.18 million	50.84 million	Optionable

CAPR, ZBIO, NUVB, and ALVO Headlines

Recent News About These Companies

Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know

October 23 at 10:56 AM | zacks.com

Morgan Stanley Begins Coverage on Zenas BioPharma (NASDAQ:ZBIO)

October 22 at 1:42 AM | americanbankingnews.com

Zenas BioPharma (NASDAQ:ZBIO) Now Covered by Morgan Stanley

October 20, 2026 | marketbeat.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Jumps 6.9% - Here's What Happened

October 19, 2026 | marketbeat.com

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 16, 2026

October 19, 2026 | biospace.comB

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 16, 2026 | globenewswire.com

Zenas BioPharma Highlights New Phase 3 Obexelimab Data

October 14, 2026 | theglobeandmail.com

Zenas BioPharma's (ZBIO) "Buy" Rating Reaffirmed at HC Wainwright

October 13, 2026 | marketbeat.com

Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release

October 13, 2026 | uk.finance.yahoo.com

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

October 12, 2026 | markets.businessinsider.com

Zenas BioPharma, Inc. (ZBIO) - What Are Analysts Thinking About This Stock?

October 12, 2026 | marketbeat.com

Zenas Biopharma Inc (ZBIO)

October 10, 2026 | investing.com

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis

October 8, 2026 | marketscreener.comM

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis

October 8, 2026 | marketscreener.comM

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.2% - Time to Sell?

October 8, 2026 | marketbeat.com

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and ...

October 7, 2026 | markets.businessinsider.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Jumps 3.3% - Should You Buy?

October 7, 2026 | marketbeat.com

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

October 7, 2026 | globenewswire.com

Zenas BioPharma to Host Virtual R&D Event on October 27, 2026

October 6, 2026 | quiverquant.comQ

Zenas BioPharma to Host Virtual R&D Event

October 6, 2026 | globenewswire.com

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

October 5, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, ZBIO, NUVB, and ALVO Company Descriptions

Alvotech NASDAQ:ALVO

$4.58 -0.21 (-4.38%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$4.58 +0.00 (+0.11%)

As of 10/23/2026 07:30 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Capricor Therapeutics NASDAQ:CAPR

$5.93 -0.20 (-3.26%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$5.97 +0.04 (+0.67%)

As of 10/23/2026 07:54 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Nuvation Bio NYSE:NUVB

$4.57 -0.13 (-2.85%)

Closing price 10/23/2026 03:59 PM Eastern

Extended Trading

$4.57 0.00 (-0.02%)

As of 10/23/2026 07:30 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Zenas BioPharma NASDAQ:ZBIO

$26.87 -1.36 (-4.82%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$26.86 -0.02 (-0.06%)

As of 10/23/2026 07:30 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ZBIO, NUVB, and ALVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ZBIO, NUVB, and ALVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ZBIO, NUVB, and ALVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, ZBIO, NUVB, and ALVO Company Descriptions

Alvotech NASDAQ:ALVO

Capricor Therapeutics NASDAQ:CAPR

Nuvation Bio NYSE:NUVB

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CAPR, ZBIO, NUVB, and ALVO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CAPR, ZBIO, NUVB, and ALVO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CAPR, ZBIO, NUVB, and ALVO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, ZBIO, NUVB, and ALVO Company Descriptions

Alvotech NASDAQ:ALVO

Capricor Therapeutics NASDAQ:CAPR

Nuvation Bio NYSE:NUVB

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools